샘플 요청 목록

 카트 문의
시장보고서
상품코드
1737371

세계의 프레가발린 시장

Pregabalin
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 372 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

프레가발린 세계 시장은 2030년까지 19억 달러에 달할 전망

2024년에 16억 달러로 추정되는 프레가발린 세계 시장은 2030년에는 19억 달러에 달하고, 분석 기간인 2024-2030년 CAGR은 2.5%로 성장할 것으로 예측됩니다. 프레가발린 이 보고서에서 분석한 부문 중 하나인 정제와 캡슐은 CAGR 2.9%를 기록하며 분석 기간 종료까지 13억 달러에 달할 것으로 예측됩니다. 기타 유형 부문의 성장률은 분석 기간 동안 CAGR 1.5%로 추정됩니다.

미국 시장은 4억 4,870만 달러로 추정, 중국은 CAGR 4.7%로 성장 예측

미국의 프레가발린 시장은 2024년에 4억 4,870만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 3억 6,360만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 4.7%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.0%와 2.1%로 예측됩니다. 유럽에서는 독일이 CAGR 1.5%로 성장할 것으로 예측됩니다.

세계의 프레가발린 시장 - 수요 급증과 혁신의 원동력은 무엇인가?

의료 및 규제 상황은 프레가발린 시장을 어떻게 형성해 왔을까?

γ-아미노부티르산(GABA) 유사체인 프레가발린은 신경인성 통증, 섬유근육통, 범불안장애(GAD), 간질 치료에 필수적인 의약품으로 부상하고 있습니다. 지난 10년간 리리카(Pfizer)와 같은 브랜드 의약품의 특허 만료에 따른 제네릭 의약품의 승인은 시장에 매우 중요한 사건으로, 보다 폭넓은 접근성과 가격경쟁을 촉진했습니다. 미국 FDA, 유럽의약품청(EMA), 일본 의약품의료기기종합기구(PMDA) 등 주요 지역 규제 당국은 경구용 캡슐제, 경구용 액제, 서방형 정제 등 다양한 제형을 순차적으로 승인하며 제품 포트폴리오를 다양화하고 있습니다. 특히 신흥 시장에서는 이러한 규제가 명확해지면서 현지 업체들이 보다 자유롭게 진입할 수 있는 여건이 조성되고 있습니다. 동시에 편두통, 양극성 장애 등 프레가발린의 적응증 외 사용이 주목받고 있지만, 아직 논란의 여지가 있습니다. 또한, 북미의 오피오이드 위기에 대한 인식이 높아지면서 처방 패턴도 변화하고 있으며, 프레가발린은 만성 통증 관리를 위한 보다 안전하고 오피오이드가 없는 대체 약물로 간주되고 있습니다. 한편, 약물감시 데이터와 임상진료지침의 업데이트는 사용 기준과 투약 패턴에 지속적으로 영향을 미치고 있습니다. 특히 인도나 브라질과 같은 국가에서는 지적 재산권의 역학관계로 인해 제네릭 의약품 간의 경쟁이 촉진되어 가격대가 더욱 낮아지고 채택이 증가하고 있습니다. 오남용 및 의존성 위험에 대한 소송과 규제 당국의 감시가 여전히 활발하지만, 진화하는 의료 정책과 함께 시장의 모멘텀은 계속 증가하고 있습니다.

진화하는 환자 인구통계와 역학 동향이 무대를 마련할 것인가?

전 세계 인구통계 및 역학의 변화는 프레가발린 수요의 가장 중요한 원동력 중 하나입니다. 특히 일본, 독일, 이탈리아 등 선진국에서는 고령화가 진행되면서 프레가발린이 처방되는 주요 질환인 신경병증성 통증과 당뇨병성 말초신경병증의 유병률이 높아지고 있습니다. 신흥국에서는 의료 접근성이 향상됨에 따라 간질이나 섬유근육통의 미진단 사례가 치료의 사각지대에 놓이는 경우가 증가하고 있어 대상 환자층이 확대되고 있습니다. 또한, 생활습관병(특히 당뇨병)의 급증은 프레가발린의 주요 응용 분야인 당뇨병성 신경장애의 증가와 직결되어 있습니다. 또한 불안장애와 같은 정신건강 문제에 대한 사회적 인식이 높아짐에 따라, 특히 도시화되고 디지털로 연결된 인구 집단에서 약리학적인 개입을 원하는 사람들이 증가하고 있습니다. 디지털 헬스 툴과 원격의료 플랫폼의 보급으로 이러한 질병에 대한 인식이 높아지면서 진단율이 향상되어 간접적으로 프레가발린 처방을 촉진하고 있습니다. 또한, COVID 이후 만성 통증 및 심리적 상태의 급증도 주목할 만하지만, 이는 COVID의 장기적인 증상과 관련이 있을 수 있으며, 이는 수요를 더욱 증폭시키고 있습니다. 농촌 인구가 고령화되는 국가에서는 통증 관리 요법을 확대하기 위한 국가 보건 프로그램이 제네릭 프레가발린 제조업체에게 새로운 미시 시장을 창출하고 있습니다.

시장 역학에서 지역적, 기술적 변화는 어떤 역할을 하는가?

헬스케어 인프라, 제조 능력, 의료 지식의 지역적 차이로 인해 복잡하면서도 유망한 프레가발린 시장 지도가 형성되고 있습니다. 북미는 선진화된 의료 시스템과 높은 인지도로 인해 금액 기준 우위를 유지하고 있지만, 아시아태평양은 인도, 중국, 남미에 힘입어 가장 활발한 성장세를 보이고 있습니다. 이들 국가에서는 제네릭 의약품의 현지 생산, 정부의 가격 규제, 보험 적용 확대가 중요한 촉진요인으로 작용하고 있습니다. 라틴아메리카와 아프리카의 일부 지역은 아직 개발 중인 시장이지만, 국제 원조 프로그램 및 현지 의약품의 확대에 따라 의약품의 접근성이 향상되어 잠재적 가능성을 보여주고 있습니다. 서방형 정제의 개발 등 약물전달 시스템의 주요 기술 발전은 치료 순응도와 환자의 편의성을 향상시켜 의사의 처방 행동에 영향을 미치는 중요한 요소로 작용하고 있습니다. 제조 공정의 혁신, 특히 거울상 이성질체 순수 화합물의 합성 및 비용 효율적인 제조 기술의 확장은 생산자의 이익률 향상으로 이어지고 있습니다. 또한, 약물감시 및 의약품 안전성 모니터링에 AI를 활용하여 시판 후 조사를 간소화하고 규제 지연을 줄이고 있으며, E-Commerce 및 환자 직접 판매 의약품 유통 채널에 대한 의존도가 높아짐에 따라 특히 디지털 성숙 경제권에서 프레가발린이 최종 소비자에게 도달하는 방식도 변화하고 있습니다. 변화하고 있습니다. 이러한 지역적, 기술적 발전의 융합은 보다 경쟁력 있는 혁신 주도형 시장을 가능하게 하고 있습니다.

프레가발린 시장의 지속적인 성장 원동력은?

세계 프레가발린 시장의 성장은 기술, 최종 용도 동향, 소비자 행동의 진화에 기반한 몇 가지 요인에 의해 주도되고 있습니다. 첫째, 특허 만료 후 제네릭 의약품 제조가 광범위하게 채택되면서 비용 장벽이 크게 낮아져 소득 계층에 관계없이 의약품에 대한 접근성이 높아졌습니다. 특히 아시아태평양에서 의약품 공급망이 현지 생산으로 전환되면서 유통 일정이 최적화되고 수입 의존도를 최소화할 수 있게 되었습니다. 최종 용도 측면에서는 고령화에 따른 만성 통증(신경인성 통증, 대상포진 후 신경통, 섬유근육통 등)의 유병률 증가가 직접적으로 시장을 확대하는 요인으로 작용하고 있습니다. 동시에 정신과 의사들이 범불안장애에 대한 프레가발린 처방에 익숙해지고 정신보건 의료에서 병용요법 처방이 증가하고 있는 것도 수요에 새로운 국면을 가져오고 있습니다. 병원, 통증클리닉, 정신보건센터 등에서 프레가발린을 표준 치료 프로토콜에 추가하는 사례가 증가하고 있습니다. 소비자 행동 측면에서는 제네릭 의약품에 대한 신뢰가 높아지고 환자 교육이 개선됨에 따라 장기적인 약리학적 치료에 대한 수용성이 증가하고 있습니다. 특히 프레가발린의 새로운 방출 메커니즘과 같이 부작용이 적고 효능이 더 높은 제제의 경우, 환자들은 현재 장기 복용 약물 요법을 더 잘 준수하고 있습니다. 또한, 디지털 건강 생태계(전화 상담, 전자 처방전, 방문 배송)의 부상으로 인해 프레가발린과 같은 특수 의약품에 대한 접근성에 대한 저항이 감소하고 있습니다. 이러한 요인들은 제약사들의 집중적인 마케팅 노력과 보험 상환의 개선과 결합하여 시장은 지속적인 성장세를 보이고 있습니다.

부문

유형(정제·캡슐, 기타 유형), 유통 채널(병원 약국, 드럭스토어·소매 약국, 온라인 프로바이더), 용도(간질, 신경병증성 통증, 기타 용도)

조사 대상 기업 사례(총 42개사)

  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Lupin Limited
  • Medley Pharmaceuticals Ltd.
  • Mylan N.V.(Viatris Inc.)
  • Novartis AG
  • Pfizer Inc.
  • Rising Pharmaceuticals
  • Sanofi
  • ScieGen Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Ltd.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정을 적용하고 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.06.12

Global Pregabalin Market to Reach US$1.9 Billion by 2030

The global market for Pregabalin estimated at US$1.6 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2024-2030. Pregabalin Tablets & Capsules, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Other Types segment is estimated at 1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$448.7 Million While China is Forecast to Grow at 4.7% CAGR

The Pregabalin market in the U.S. is estimated at US$448.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$363.6 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global "Pregabalin" Market - What's Fueling the Surge in Demand and Innovation?

How Has the Medical and Regulatory Landscape Shaped the Pregabalin Market?

Pregabalin, a gamma-aminobutyric acid (GABA) analog, has emerged as a vital pharmaceutical compound in the treatment of neuropathic pain, fibromyalgia, generalized anxiety disorder (GAD), and epilepsy. Over the past decade, the approval of generic versions following the patent expiry of branded formulations like Lyrica (by Pfizer) has been a pivotal moment for the market, catalyzing broader accessibility and price competitiveness. Regulatory bodies in major regions including the U.S. FDA, EMA, and Japan’s PMDA have progressively approved various formulations-oral capsules, oral solutions, and extended-release tablets-creating a more diversified product portfolio. This evolving regulatory clarity, especially in emerging markets, is enabling local manufacturers to enter the scene more freely. Simultaneously, off-label uses of Pregabalin, such as for migraine and bipolar disorder, are seeing increased attention, although still debated. Prescription patterns have also shifted due to heightened awareness of the opioid crisis in North America, with Pregabalin increasingly being seen as a safer, non-opioid alternative for chronic pain management. Meanwhile, pharmacovigilance data and updated clinical practice guidelines continue to influence usage norms and dosage patterns. Intellectual property dynamics, especially in countries like India and Brazil, have fostered competition among generics, further reducing price points and increasing adoption. While litigation and regulatory scrutiny over misuse and dependence risks remain active, the market momentum continues to build in tandem with evolving health policies.

Could Evolving Patient Demographics and Epidemiological Trends Be Setting the Stage?

Demographic and epidemiological transformations globally are among the most significant underlying drivers of Pregabalin demand. Aging populations, especially in developed nations like Japan, Germany, and Italy, are associated with a higher prevalence of neuropathic pain and diabetic peripheral neuropathy, key conditions for which Pregabalin is prescribed. As healthcare access improves in emerging economies, underdiagnosed cases of epilepsy and fibromyalgia are increasingly being brought into the treatment net, expanding the target patient pool. Furthermore, the sharp rise in lifestyle diseases-most notably diabetes-is directly correlating with an increase in diabetic neuropathies, a core application area for Pregabalin. Additionally, the growing societal recognition of mental health issues such as anxiety disorders is leading to more people seeking pharmacological interventions, especially in urbanized and digitally connected populations. This heightened disease awareness, bolstered by widespread digital health tools and telemedicine platforms, has improved diagnosis rates, indirectly boosting Pregabalin prescriptions. Also noteworthy is the post-COVID surge in chronic pain and psychological conditions, potentially linked to long COVID symptoms, further amplifying demand. In countries with aging rural populations, national health programs aimed at expanding pain management therapies have inadvertently created new micro-markets for generic Pregabalin producers.

What Role Do Regional and Technological Shifts Play in Market Dynamics?

Regional variations in healthcare infrastructure, manufacturing capacity, and medical literacy are creating a complex yet promising Pregabalin market map. North America continues to dominate in terms of value due to its advanced healthcare system and high awareness levels, while Asia-Pacific is showing the most aggressive growth, led by India, China, and South Korea. In these countries, local production of generics, government price caps, and expanding insurance coverage are critical enablers. Latin America and parts of Africa are still nascent markets but show latent potential as international aid programs and local pharmaceutical expansions improve drug availability. Technological advancements in drug delivery systems-such as the development of extended-release Pregabalin tablets-are improving treatment compliance and patient convenience, a key factor influencing physicians' prescribing behavior. Innovations in manufacturing processes, particularly in the synthesis of enantiomerically pure compounds and the scaling of cost-effective production techniques, are leading to improved margins for producers. Furthermore, the use of AI in pharmacovigilance and drug safety monitoring is streamlining post-marketing surveillance and reducing regulatory delays. The increasing reliance on e-commerce and direct-to-patient drug distribution channels is also changing how Pregabalin reaches end-users, especially in digitally mature economies. The convergence of these regional and technological developments is enabling a more competitive and innovation-driven marketplace.

What Is Powering the Sustained Growth of the Pregabalin Market?

The growth in the global Pregabalin market is driven by several factors that are firmly rooted in technology, end-use trends, and evolving consumer behavior. Firstly, the widespread adoption of generic manufacturing post-patent expiry has significantly lowered cost barriers, making the drug more accessible across income tiers. The pharmaceutical supply chain’s shift toward local production, especially in Asia-Pacific, has also optimized distribution timelines and minimized import dependency. On the end-use front, the escalating prevalence of chronic pain conditions-neuropathic pain, postherpetic neuralgia, and fibromyalgia-among aging demographics has directly expanded the addressable market. Simultaneously, psychiatrists’ increasing comfort with prescribing Pregabalin for generalized anxiety disorders and the uptick in prescriptions for combination therapy in mental health care have added a new dimension to demand. Hospitals, pain clinics, and mental health centers are increasingly incorporating Pregabalin in their standard treatment protocols. From a consumer behavior standpoint, there is greater receptivity to long-term pharmacological treatments due to increased trust in generics and improved patient education. Patients are now more compliant with extended-use medications, especially when formulations promise fewer side effects and higher efficacy, which Pregabalin’s newer release mechanisms often provide. Additionally, the rise of digital health ecosystems-teleconsultations, e-prescriptions, and doorstep delivery-has reduced the inertia in accessing specialized medications like Pregabalin. These factors, combined with targeted marketing efforts by pharmaceutical companies and better insurance reimbursement coverage, are collectively steering the market toward sustained expansion.

SCOPE OF STUDY:

The report analyzes the Pregabalin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Tablets & Capsules, Other Types); Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers); Application (Epilepsy, Neuropathic Pain, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Lupin Limited
  • Medley Pharmaceuticals Ltd.
  • Mylan N.V. (Viatris Inc.)
  • Novartis AG
  • Pfizer Inc.
  • Rising Pharmaceuticals
  • Sanofi
  • ScieGen Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Pregabalin - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Neuropathic Pain Drives Demand for Pregabalin Therapies
    • Increasing Diagnosis of Generalized Anxiety Disorder Expands Addressable Market for Pregabalin
    • Growing Geriatric Population Propels Use of Pregabalin in Chronic Pain Management
    • Regulatory Approvals for Additional Indications Strengthen Business Case for Expanded Use
    • Generic Erosion Post-Patent Expiry Spurs Market Competition and Price Accessibility
    • Surge in Off-Label Prescriptions Throws Spotlight on Regulatory Oversight and Clinical Guidelines
    • Online Pharmacy Growth and Telemedicine Platforms Fuel Wider Distribution of Pregabalin
    • Concerns Over Dependency and Abuse Potential Drive Interest in Controlled Dispensing Protocols
    • Rise in Epilepsy Cases in Emerging Markets Generates Demand for Affordable Pregabalin Formulations
    • Combination Therapy Approaches in Psychiatry Accelerate Use of Pregabalin in Multimodal Treatments
    • Growing Demand for Non-Opioid Pain Management Strengthens Pregabalin Market Position
    • Technological Innovations in Drug Delivery Systems Boost Extended-Release Pregabalin Development
    • Increased Payer Focus on Cost-Effective Treatment Options Supports Generic Adoption
    • Post-Marketing Surveillance and Pharmacovigilance Shape Market Sentiment and Prescriber Behavior
    • Cross-Border Sales and Parallel Imports Create Opportunities and Compliance Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pregabalin Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pregabalin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pregabalin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Pregabalin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Tablets & Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Tablets & Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Tablets & Capsules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Epilepsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Neuropathic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Pregabalin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Pregabalin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Pregabalin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Pregabalin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Pregabalin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Pregabalin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Pregabalin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Pregabalin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Pregabalin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Pregabalin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Pregabalin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제